Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-31

Study Completion Date

2021-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urinary tract infections (UTIs) are bothersome and more likely to occur in postmenopausal women. Frequent UTIs, as well as other problems with the urinary and genital systems such as painful sex and urinary frequency/urgency, are part of a symptom complex called genitourinary syndrome of menopause (GSM). Prasterone (Intrarosa®) is a man-made steroid that helps with painful sex in postmenopausal women. Because previous studies have shown prasterone to help with other GSM problems, this study was designed to investigate if prasterone used in the vagina decreases the number of UTIs in postmenopausal women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

NCT04493333

Vaginal Atrophy Postmenopausal Symptoms Breast Cancer Female +1 more

TERMINATED PHASE2

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

NCT01958073

Recurrent Urinary Tract Infection

COMPLETED PHASE4

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

NCT03782480

Menopause Genitourinary Syndrome of Menopause Vulvovaginal Atrophy +2 more

UNKNOWN PHASE3

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349

Breast Cancer Gynecologic Cancer

COMPLETED PHASE3

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

NCT04807894

Recurrent Urinary Tract Infection Vaginal Atrophy Postmenopausal Disorder

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Urinary tract infections (UTIs) are costly contributing to more than 8 million ambulatory visits (84% women) in the United States in 2007. Recurrent urinary tract infections (rUTIs) are UTIs diagnosed on at least 2 urine cultures in 6 months, or at least 3 in 1 year. The incidence of rUTIs increases in menopause with an estimated 10-15% of women \> 60 years old having rUTIs. rUTIs contribute to a constellation of bothersome genitourinary symptoms in some postmenopausal women called genitourinary syndrome of menopause (GSM). Thus, menopause, rUTIs, and GSM are intimately linked.

Prasterone (Intrarosa®) is a synthetic version of the steroid, dehydroepiandrosterone (DHEA), approved by the US Food and Drug Administration in 2016 for the treatment of moderate to severe dyspareunia due to GSM. Large, prospective studies have shown prasterone to safely decrease vaginal pH, decrease parabasal cells, increase superficial cells, and decrease symptoms related to atrophy like dyspareunia in women with GSM. Given prasterone's favorable treatment effects on some GSM symptoms, investigation of prasterone as a possible treatment option for rUTIs in the setting of GSM is warranted.

This is a single center, double-blind, placebo-controlled, randomized trial comparing the efficacy of nightly intravaginal prasterone for 24 weeks to intravaginal placebo in decreasing rUTIs in women with GSM. The study hypothesis is that intravaginal prasterone decreases UTI incidence in women with GSM compared to placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Urinary Tract Infection Postmenopause Postmenopausal Syndrome Postmenopausal Symptoms Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravaginal prasterone insert

Nightly intravaginal prasterone insert for 24 weeks

Group Type ACTIVE_COMPARATOR

Prasterone

Intervention Type DRUG

Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.

Intravaginal placebo insert (Witepsol H-15)

Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prasterone

Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.

Intervention Type DRUG

Placebo

Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Intrarosa Dehydroepiandrosterone DHEA Witepsol H-15 Witepsol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged 18 years or older who are ≥ 1 year after spontaneous or surgical (bilateral oophorectomy) menopause
* Presence of ≤ 5% of superficial cells on vaginal smear and vaginal pH \> 5.0
* History of ≥ 2 UTIs in 6 months or ≥ 3 UTIs in 12 months (with documentation of a UTI confirmed on urine culture within the past 1 year)
* Negative urine culture prior to treatment randomization

Exclusion Criteria

* Known allergy/hypersensitivity to prasterone or its constituents
* Contraindications to estrogen: acute thrombophlebitis, history of blood clotting disorder, and/or personal history of thromboembolic disorder associated with estrogen use
* Known or suspected estrogen-dependent neoplasms or mammary, ovarian, cervical, or vaginal malignancies
* Known congenital urologic or gynecologic abnormality
* Chronic immunosuppression
* Need for chronic catheterization
* Vaginal bleeding of origin other than vaginal mucosal atrophy
* Vaginal infection requiring treatment
* Use of systemic hormone replacement therapy or estrogen within past 6 months
* Use of topical estrogen within past 3 months
* Consistent use of vaginal products (lubricants, douches)
* Ongoing antibiotic treatment
* Ongoing treatment with Lactobacillus
* Inability to comply with protocol or place vaginal insert with applicator appropriately
* Less than 3 months status post urinary incontinence and/or pelvic organ prolapse surgery
* Unable to speak or read English
* If an exclusion condition is resolved, the patient may be re-approached later for study recruitment (ie., genitourinary infection, use of antibiotics, etc)

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No